ArticleCell reports2020
Evaluation of Engineered CRISPR-Cas-Mediated Systems for Site-Specific RNA Editing.
Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Light-Controlled Assembly and Disassembly of Covalent RNA-Protein Conjugates to Control RNA Base Editing.Molecules (Basel, Switzerland) · 2026Article
- The regulatory mechanism and clinical significance of RNA editing in prostate cancer.Current urology · 2026Review
- Target-stabilized base editors enable robust high-fidelity RNA editing.Nature communications · 2026Article
- Development and validation of a machine learning model for predicting hypersplenism in Wilson disease patients.Frontiers in medicine · 2026Article
- CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential.Cell proliferation · 2025Article
- Application of CRISPR-Cas9 in microbial cell factories.Biotechnology letters · 2025Review
- Enhancing RNA editing efficiency and specificity with engineered ADAR2 guide RNAs.Molecular therapy. Nucleic acids · 2025Article
- Chemical engineering of CRISPR-Cas systems for therapeutic application.Nature reviews. Drug discovery · 2025Review
- Important applications of DNA nanotechnology combined with CRISPR/Cas systems in biotechnology.RSC advances · 2025Review
- Programmed RNA editing with an evolved bacterial adenosine deaminase.Nature chemical biology · 2024Article
- Deconstructing cancer with precision genome editing.Biochemical Society transactions · 2024Review
- RNA editing enzymes: structure, biological functions and applications.Cell & bioscience · 2024Review
- Programmable RNA base editing via targeted modifications.Nature chemical biology · 2024Review
- Precision RNA base editing with engineered and endogenous effectors.Nature biotechnology · 2023Review
- Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders.RNA (New York, N.Y.) · 2023Article
- Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology.Translational psychiatry · 2023Review
- Engineering synthetic RNA devices for cell control.Nature reviews. Genetics · 2022Review
- Targeted RNA editing: novel tools to study post-transcriptional regulation.Molecular cell · 2022Review
- Genome Editing among Bioethics and Regulatory Practices.Biomolecules · 2021Review
- Programmable technologies to manipulate gene expression at the RNA level.Current opinion in chemical biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Site-directed RNA editing approaches offer great potential to correct genetic mutations in somatic cells while avoiding permanent off-target genomic edits. Nuclease-dead RNA-targeting CRISPR-Cas systems recruit functional effectors to RNA molecules in a programmable fashion. Here, we demonstrate a Streptococcus pyogenes Cas9-ADAR2 fusion system that uses a 3' modified guide RNA (gRNA) to enable adenosine-to-inosine (A-to-I) editing of specific bases on reporter and endogenously expressed mRNAs. Due to the sufficient nature of the 3' gRNA extension sequence, we observe that Cas9 gRNA spacer sequences are dispensable for directed RNA editing, revealing that Cas9 can act as an RNA-aptamer-binding protein. We demonstrate that Cas9-based A-to-I editing is comparable in on-target efficiency and off-target specificity with Cas13 RNA editing versions. This study provides a systematic benchmarking of RNA-targeting CRISPR-Cas designs for reversible nucleotide-level conversion at the transcriptome level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.